- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07869355
BRE-13: Mediterranean Diet (BRE-13)
BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer
Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Kosttillskott: Explore the effect of MedDiet vs. Usual Diet on Fatty Acid Profile
- Diagnostiskt test: Explore the effect of MedDiet vs. Usual Diet on Breast Tumor Tissue
- Diagnostiskt test: Explore the effect of MedDiet vs. Usual Diet on Lipids
- Diagnostiskt test: Explore the effect of MedDiet vs. Usual Diet on tumor tissue expression
Detaljerad beskrivning
Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Lisa Marie Tussing-Humphreys, Ph.D.
- Telefonnummer: 312 355 5521
- E-post: tussing@uic.edu
Studera Kontakt Backup
- Namn: Meredith Russell
- Telefonnummer: 312 355 5112
- E-post: mrussel3@uic.edu
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Rekrytering
- University of Illinois at Chicago Campus
-
Kontakt:
- Meredith Russell, BS
- Telefonnummer: 312 355 5112
- E-post: mrussel3@uic.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years;
- Newly diagnosed stage I-III luminal breast cancer
- Planned surgical resection at UI Health
- Ability to speak, read, write, and understand English
- A Mediterranean Eating Pattern for Americans (MEPA-III) score <13 indicating that they do not currently follow a MedDiet;
- ECOG performance status of 0 or 1.
Exclusion Criteria:
- Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet;
- Lack of access to a space to safely store and reheat foods items;
- Living in facility that provides meals;
- Chronic CKD stage 3+ or currently receiving dialysis treatment;
- History of GI surgery involving removal of part of the stomach or intestines;
- Type 1 or Type 2 diabetes;
- Autoimmune or Inflammatory disease or immunocompromised; and
- Cachexia.
We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Med Diet
Mediterranean Diet (MedDiet) is a dietary pattern characterized by a low intake of saturated fats and a high intake of unsaturated fats, with olive oil as the primary culinary fat (7, 8). |
Fatty acid profile (chain length and degree of saturation) in circulation of blood, tumor tissue, and tumor interstitial fluid. Fatty acid profile (chain length and degree of saturation) in breast tumor tissue. Lipid availability in blood, tumor tissue, and tumor interstitial fluid. Tumor tissue will explore the effect of MedDiet vs. Usual Diet on tumor proliferation (Ki67) and expression of NK and CD8 T cells and chylomicrons (Apo48 staining). |
|
Inget ingripande: Usual Diet
Dietary fat and cancer has been conducted in preclinical models of diet-induced obesity, where high-fat diets promote tumor growth |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Aim 1a
Tidsram: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in blood. |
3 weeks
|
|
Aim 1b
Tidsram: 3 weeks
|
Lipid availability in blood, tumor tissue, and interstitial fluid. |
3 weeks
|
|
Aim 1c
Tidsram: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in breast tumor tissue, |
3 weeks
|
|
Aim 2a
Tidsram: 3 weeks
|
peripheral blood monocyte cells from the electronic health record. |
3 weeks
|
|
Aim 2b
Tidsram: 3 weeks
|
Tumor tissue will explore the effects on tumor proliferation (Ki67) cells. |
3 weeks
|
|
Aim 2c
Tidsram: 3 weeks
|
Tumor tissue will explore the effects on expression of NK cells. |
3 weeks
|
|
Aim 2d
Tidsram: 3 weeks
|
Tumor tissue will explore the effects on CD8 T cells(immunohistochemistry) cells. |
3 weeks
|
|
Aim 2e
Tidsram: 3 weeks
|
Tumor tissue will explore the effects on chylomicrons (Apo48 staining) cells. |
3 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Exploratory aim a
Tidsram: 3weeks
|
Stool will be used to analyze gut microbiome changes using shotgun bioinformatics and downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim b
Tidsram: 3weeks
|
Stool will be used to analyze downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim c
Tidsram: 3weeks
|
Stool will be used to analyze metabolic changes among the two study arms. |
3weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Lisa Marie Tussing-Humphreys, Ph.D, University of Illinois Chicago Campus
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026-0573
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .